10 November 2021 - Roche, still months away from seeking regulatory approval of its experimental Alzheimer's drug, is already taking aim at rival Biogen's Aduhelm, saying that its medication would be priced competitively.

Bill Anderson, head of pharmaceuticals at Roche, did not provide pricing details for the company's treatment for the lethal brain-wasting disease, but indicated in an interview that it could be priced below Aduhelm's $56,000/year cost. 

Anderson said Roche has taken similar action in the past, including for multiple sclerosis drug Ocrevus, which was launched at a price 30% below the standard of care.

Read Reuters article